Vitiligo is a chronic autoimmune skin disorder characterized by the loss of melanocytes and the appearance of white patches on the skin,which can lead to various psychological disorders in patients.Ruxolitinib cream,a topical formulation of selective JAK1/2 inhibitor,was successively approved by the Food and Drug Administration(FDA)in July 2022 and the European Commission(EC)in April 2023 for the local treatment of non-segmental vitiligo in adults and children aged over 12 years.Numerous clinical studies have demonstrated that Ruxolitinib cream has a definite therapeutic effect on vitiligo,with good safety and tolerability.This article provides a comprehensive review of the mechanism of action,pharmacological effects,pharmacokinetics,clinical efficacy,and safety of Ruxolitinib cream,aiming to offer a reference for the clinical treatment of vitiligo.
NETL
NSTL
万方数据
